AMAnuradha Mehra

Anuradha Mehra

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Anuradha Mehra has a total of 23 co-authors. Here are the top co-authors by number of shared publications:

  • Amit Mittal

    Department of Pharmaceutical Chemistry, School of Pharmaceutical Sciences, Lovely Professional University, Jalandhar-Delhi G.T. Road (NH-1), Phagwara (Punjab), 144411, India

    18 shared publications
  • Rekha Sangwan

    Department of Pharmaceutical Chemistry, School of Pharmaceutical Sciences, Lovely Professional University

    12 shared publications
  • Aryan Mehra

    Department of Mechanical Engineering, Lovely Professional University, Jalandhar-Delhi G.T. Road (NH-1), Phagwara (Punjab) 144411, India

    4 shared publications
  • Amit Mittal

    Lovely Professional University

    3 shared publications
  • Anu Mittal

    Department of Chemistry, Guru Nanak Dev University College, Patti (Punjab)143416, India

    2 shared publications
  • Honey Saini

    Department of Pharmaceutical Chemistry, School of Pharmaceutical Sciences, Lovely Professional University, Jalandhar-Delhi G.T.Road (NH-1), Phagwara (Punjab), 144411, India

    2 shared publications

Latest Publications

  • Phytochemicals in Alzheimer’s disease: Mechanistic Insights, Targets, and Future Directions

    by Anuradha Mehra, Amit Mittal

    Alzheimer’s disease (AD) is a progressive neurodegenerative disorder characterized by memory impairment, cognitive decline, and behavioral alterations. It is the most common form of dementia among older adults and represents a major global health, social, and economic burden. Current pharmacological interventions primarily provide symptomatic relief and have limited efficacy in preventing or reversing the underlying disease pathology, highlighting the need for alternative and innovative therapeutic approaches. Natural compounds with neuroprotective properties have demonstrated considerable potential for targeting multiple pathological mechanisms associated with AD. Phytochemicals, including polyphenols, alkaloids, terpenoids, flavonoids, and other bioactive constituents widely found in fruits, vegetables, herbs, and medicinal plants, exhibit diverse and complementary mechanisms of action. These include inhibition of acetylcholinesterase (AChE), suppression of amyloid-β aggregation, antioxidant and anti-inflammatory activities, and modulation of key signaling pathways involved in neuronal survival and synaptic plasticity. Ginsenosides derived from ginseng, resveratrol from grapes, curcumin from turmeric, and epigallocatechin gallate (EGCG) from green tea are among the most extensively studied phytochemicals and have demonstrated promising neuroprotective effects in numerous preclinical models. These compounds may exert multitarget effects against several pathological hallmarks of AD, offering potential advantages over conventional pharmacological approaches that primarily target individual disease mechanisms. This review provides a comprehensive overview of the therapeutic potential and mechanisms of action of major phytochemicals, with particular emphasis on their prospective applications in the development of novel therapeutic agents and evidence-based preventive strategies for AD.

  • Cholinesterase Inhibitors in Alzheimer's Disease: Medicinal Chemistry, Mechanistic Insights, and Emerging Multitarget Strategies

    by Anuradha Mehra, Rahul Sharma, Amit Mittal

    Alzheimer's disease (AD) is the leading neurodegenerative disorder in the world. Although several decades of research have focused on its multifactorial pathogenesis, treating it remains a great challenge. The approved treatment options include cholinesterase inhibitors (ChEIs), which are the most common symptomatic treatment choice. These drugs act by inhibiting acetylcholinesterase (AChE) and, in some cases, butyrylcholinesterase (BuChE), preventing the breakdown of acetylcholine and increasing cholinergic neurotransmission in the brain. This review provides a broad consideration of ChEIs, focusing on their bioactivity, biochemical action, clinical significance, and SAR trends. It provides a comparative analysis of all the major chemical classes of ChEIs, namely the carbamates and organophosphates, as well as multiple heterocyclic scaffolds, with particular assessment of BBB permeability, metabolic stability, and toxicity attributes. Recent advances in medicinal chemistry have led to a shift in interest toward multi-target-directed ligands (MTDLs) that are designed not only to inhibit ChEs but also to exert antioxidant, anti-inflammatory, anti-amyloid, and metalchelating activity. These can target multiple pathogenic mechanisms to achieve a better therapeutic effect and neuroprotection. This review is based on a robust literature search conducted between 2020 and 2025. The progress, limitations, and prospects of ChEIs in the treatment of AD are critically assessed in this work. It also underscores the need for rational drug design to develop multitargetdirected drugs that may have disease-modifying effects, to overcome the limitations of existing symptomatic cholinesterase-inhibitor monotherapy.

  • SAR and mechanistic pathways of oxadiazole derivatives: targeting enzymes for antidiabetic therapy

    by Anuradha Mehra, Amit Mittal

    Diabetes mellitus is a chronic metabolic disorder characterized by persistent hyperglycemia resulting from impaired insulin secretion, insulin action, or both (Mehra 2024; Mehra et al. 2024). The g...


  • Thiazolidinedione nucleus: a molecular beacon in treatment of diabetes

    by Anuradha Mehra, Amit Mittal, Shivangi Singh

    1. Type 2 diabetes mellitus (T2DM) is a long-term chronic metabolic disease that is associated with insulin resistance and insulin-secreting dysfunction, resulting in chronic hyperglycemia [1]. The...


  • Polyphenols in Cancer Therapy: Recent Advances, Mechanistic Pathways, and Therapeutic Insights

    by Anuradha Mehra, Amit Mittal

    Polyphenols are naturally occurring compounds characterized by multiple hydroxyl groups attached to aromatic rings. They are broadly classified into four major groups: flavonoids, phenolic acids, lignans, and stilbenes. They act through a number of multiple signalling pathways, including MAPK, PI3K/ Akt, NF-κB, and STAT3 pathways, which induce apoptosis and programmed cancer cell death, which is frequently linked to the development of cancer. Additionally, polyphenols have synergistic effects with chemotherapeutic medications, which makes them attractive options for individual and combination therapy. This review includes studies published between 2019 and 2025 on polyphenols with anti-cancer potential in both in vitro and in vivo analysis. This review integrates recent evidence with a mechanism-based mapping of polyphenol classes to specific anticancer signaling pathways, offering an updated and clinically relevant perspective rarely captured in earlier reviews.


  • Recent Triazoles Targeting HIV

    by Anuradha Mehra, Siddhanshu Batra, Rekha Sangwan

  • Decoding the Anticancer Potential of Natural N-Heterocycles: Molecular Frameworks, Bioactivity, and Mechanistic Advances

    by Honey Saini, Anuradha Mehra, Amit Mittal

    Cancer is the leading cause of death and morbidity worldwide. Numerous scientists are trying to develop new anticancer medications that are more potent and less hazardous. This review, in contrast to previous reviews, focuses on the latest research findings from 2020–2025 on N-heterocyclic moieties as natural anticancer agents. This review provides a contemporary evaluation that integrates recent mechanistic discoveries, emerging nanotechnology-based delivery approaches, and translational progress relevant to natural Nheterocyclic anticancer agents. The literature was collected from online sources such as PubMed, Science Direct, Embase, and Google Scholar by searching with keywords like research paper on Natural N-heterocyclic products having anticancer activity, etc. The findings suggest that combining naturally obtained N-heterocyclic compounds with nanotechnology can provide us with a low-toxic anticancer drug in the future. The process of combining natural products containing N-Heterocyclic moieties with nanotechnology can be a game-changer for the development of anticancer medications. Still, there is a lot of research to be done in this area, which can change the viewpoint of the world regarding the treatment of cancer.

  • Targeting EGFR With Indole Derivatives: Recent Advances and Therapeutic Perspectives

    by Tanishq Verma, Anuradha Mehra, Amit Mittal

    Worldwide, cancer is a leading cause of morbidity and mortality. While multiple EGFR inhibitors have emerged, their therapeutic efficacy is constrained by the development of drug resistance and long‐term toxicity. Indoles have been identified as one of the promising scaffold classes to compete against EGFR in terms of selectivity and potency. They are favorable for anticancer drug discovery because they are structurally plastic, possess favorable pharmacokinetics, and bind to the ATP‐binding pocket of EGFR. Indole derivatives inhibit the auto‐phosphorylation of EGFR, thereby exhibiting their activity against cancers by blocking cancer cell proliferation, survival, and metastasis. The translation potential of this scaffold is also supported by the clinical success of indole‐based EGFR inhibitors, including the third‐generation drug osimertinib. Recent advances in molecular docking, structure–activity relationship studies, and hybrid drug design highlight the potential of indole‐based scaffolds to address resistance mutations while minimizing side effects. This paper summarizes the relevant literature of indole EGFR inhibitors published between 2021 and 2025, which may include mechanistic insights, biological screening, and therapeutic potential. The indole scaffold can be a useful starting point to push forward the next generation of targeted cancer therapies.


  • Metabolic and Pharmacokinetic Perspectives on Hepatotoxic Agents in Experimental Cirrhosis

    by Anuradha Mehra, Roopal Mittal, Amit Mittal, Rekha Sangwan, Tanmoy Roy, Anu Mittal, Neha Raj, Ruchi Kohli

    Cirrhosis is a very serious, gradual liver disease characterized by the overproduction of collagen and scarring, which together may result in liver failure or hepatocellular cancer. It typically develops based on fibrosis, which may be reversible when diagnosed in its initial stages. Viral hepatitis, alcohol, non-alcoholic fatty liver disease, and drug-induced hepatotoxicity are some of the etiologies of the disease. It is worth noting that about half of the cases of hepatic damage in patients are known to be caused by drug-induced liver injury. The existence of the pathophysiological complexity and therapeutic reactions of cirrhosis requires experimental models that are reliable. This review gives insight into the different in vivo, ex vivo, and operative animal models employed to cause hepatic injury by application of chemicals, drugs, dietary, and bile duct ligation particulars. The focus is on the mechanistic understanding of the actions of hepatotoxic substances, their involvement in oxidative stress, mitochondrial pathology, and the inflammatory process. Each model is critically discussed in terms of its advantages, limitations, and translational relevance.Additionally, this work highlights emerging alternatives, such as organ-on-a-chip systems, 3D co-cultures, and hepatic bioengineered tissues, as solutions that aim to reduce animal use and increase physiological relevance. The review also discusses biomarkers, histopathological endpoints, and important molecular players in hepatic fibrosis and cirrhosis. The review also examines data from preclinical studies of hepatoprotective substances and modulators of fibrosis, as it facilitates the integration of data from various experimental platforms. The next steps involve personalized pathology based on decellularized liver scaffolding and patient cells, aiming to better determine clinical outcomes and treatment responses.


  • A Review of the Therapeutical Perspective of Phytochemicals in the Treatment of HIV

    by Shubham Kumar Srivastwa, Anuradha Mehra, Rekha Sangwan

    HIV/AIDS is one of the most widespread global diseases. It is caused by the human immunodeficiency virus (HIV), which leads to the development of acquired immunodeficiency syndrome (AIDS). In AIDS patients, the immune system progressively weakens, making them vulnerable to various infections and cancers. The virus can be transmitted through the exchange of bodily fluids such as blood, semen, vaginal fluid, and breast milk, where HIV can be found in both free virus particles and infected immune cells. Although drug resistance remains a challenge for HIV/AIDS treatment, researchers are exploring the use of natural substances in the development of anti-HIV drugs. Clinical trials based on plant-derived compounds are currently being conducted. Experimental research suggests that plants may have the potential to treat HIV. However, the identification of active compounds, testing of extracts, and creation of suitable bioassays are all complex processes. Natural product scientists face the challenge of separating these complicated extracts into their active components. Various phytochemicals found in Astragalus membranaceus Bunge, Chelidonium majus L, Combretum molle (R. Br. ex. G. Don.) Engl& Diels, Dittrichiaviscosa (L.) Greuter, Helichrysum populifolium, Hoodia gordonii (Masson) Sweet ex Decne, and Hypericumperf, have been investigated pharmacologically and pharmacokinetically. Further research is needed to optimize formulations and production in accordance with preclinical safety and efficacy studies.